Sustained remission of multi-line relapsed extranodal NK/T-cell lymphoma, nasal type, following sintilimab and chidamide: A case report.

ABSTRACT:

Introduction

There is currently no optimal treatment modality for refractory or relapsed Extranodal NK/T-cell lymphoma, nasal type (ENKTL). In recent years, programmed cell death protein 1 (PD-1)/programmed cell - ligand 1 pathway blockade and histone deacetylase inhibitors have emerged as promising strategies for refractory or relapsed ENKTL. Accumulating evidence has shown that therapeutic effects of anti-PD-1 antibody could be enhanced by histone deacetylase inhibitors.

Patient concerns

A 52-year-old male patient was diagnosed with stage I ENKTL by biopsy on February 2010.

Diagnosis

positron emission tomography-computed tomography (PET-CT) and biopsy were used to diagnose relapsed ENKTL in 2014.

Interventions

The patient was treated with radiotherapy and six

SUBMITTER: Xu J 

PROVIDER: S-EPMC7969288 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature